Nucresiran vs Vutrisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Cardiomyopathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Cardiomyopathy pipeline

Nucresiran

Developed by Alnylam Pharmaceuticals

Phase 3 in Transthyretin Amyloidosis with CardiomyopathyRNAi
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2030 · NCT07052903 (registry estimate)

No aligned efficacy figure on record for this race.

Vutrisiran · AMVUTTRA

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with CardiomyopathyRNAi
Reliable signal

NCT04153149 · Phase 3 · active, not recruiting

HELIOS-B randomised 655 patients with transthyretin amyloid cardiomyopathy to vutrisiran or placebo under quadruple masking. Both primary analyses of the clinical composite endpoint (all-cause death and recurrent cardiovascular events) were met: HR 0.718 (p=0.0118) in the overall population and HR 0.672 (p=0.0162) in the monotherapy subgroup.

Next expected readout: March 2028 · NCT06679946 (registry estimate)

Reported efficacy

Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population (Up to Month 36); Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy Subgroup (Up to Month 36): Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 (met)

Result source: NCT04153149

Results for Transthyretin Amyloidosis with Cardiomyopathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Cardiomyopathy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Vutrisiran
Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 NCT04153149 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Transthyretin Amyloidosis with Polyneuropathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline

Nucresiran

Developed by Alnylam Pharmaceuticals

Phase 3 in Transthyretin Amyloidosis with PolyneuropathyRNAi
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07223203 (registry estimate)

No aligned efficacy figure on record for this race.

Vutrisiran · AMVUTTRA

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with PolyneuropathyRNAi
Partial signal

NCT03759379 · Phase 3 · completed

This was a randomized but open-label study, and its primary comparison used 122 vutrisiran-treated participants versus 77 participants from an external APOLLO placebo group rather than a concurrent blinded placebo arm. The clinical primary endpoint, change in mNIS+7 at Month 9, favored vutrisiran and was statistically significant, but the lack of blinding and use of an external comparator limit the strength of the evidence.

Reported efficacy

Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) (met)

Result source: NCT03759379

Results for Transthyretin Amyloidosis with Polyneuropathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Polyneuropathy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Vutrisiran
Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) NCT03759379 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nucresiran's landscape · Vutrisiran's landscape